Review





Similar Products

pan caspase inhibitor quinoline val asp difluorophenoxymethylketone  (MedChemExpress)
96
MedChemExpress pan caspase inhibitor quinoline val asp difluorophenoxymethylketone
Pan Caspase Inhibitor Quinoline Val Asp Difluorophenoxymethylketone, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor quinoline val asp difluorophenoxymethylketone/product/MedChemExpress
Average 96 stars, based on 1 article reviews
pan caspase inhibitor quinoline val asp difluorophenoxymethylketone - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
pan caspase inhibitor z vad fmk  (InvivoGen)
96
InvivoGen pan caspase inhibitor z vad fmk
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Pan Caspase Inhibitor Z Vad Fmk, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor z vad fmk/product/InvivoGen
Average 96 stars, based on 1 article reviews
pan caspase inhibitor z vad fmk - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
pan caspase inhibitor z vad fmk  (MedChemExpress)
96
MedChemExpress pan caspase inhibitor z vad fmk
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Pan Caspase Inhibitor Z Vad Fmk, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor z vad fmk/product/MedChemExpress
Average 96 stars, based on 1 article reviews
pan caspase inhibitor z vad fmk - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
pan caspase inhibitor z vadfmk  (MedChemExpress)
96
MedChemExpress pan caspase inhibitor z vadfmk
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Pan Caspase Inhibitor Z Vadfmk, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor z vadfmk/product/MedChemExpress
Average 96 stars, based on 1 article reviews
pan caspase inhibitor z vadfmk - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
z vad fmk pan caspase inhibitor  (InvivoGen)
96
InvivoGen z vad fmk pan caspase inhibitor
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Z Vad Fmk Pan Caspase Inhibitor, supplied by InvivoGen, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/z vad fmk pan caspase inhibitor/product/InvivoGen
Average 96 stars, based on 1 article reviews
z vad fmk pan caspase inhibitor - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
pan caspase inhibitor hy 16658b final  (MedChemExpress)
96
MedChemExpress pan caspase inhibitor hy 16658b final
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Pan Caspase Inhibitor Hy 16658b Final, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor hy 16658b final/product/MedChemExpress
Average 96 stars, based on 1 article reviews
pan caspase inhibitor hy 16658b final - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
pan caspase inhibitor  (MedChemExpress)
95
MedChemExpress pan caspase inhibitor
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Pan Caspase Inhibitor, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor/product/MedChemExpress
Average 95 stars, based on 1 article reviews
pan caspase inhibitor - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
pan caspase inhibitor cas  (TargetMol)
93
TargetMol pan caspase inhibitor cas
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Pan Caspase Inhibitor Cas, supplied by TargetMol, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor cas/product/TargetMol
Average 93 stars, based on 1 article reviews
pan caspase inhibitor cas - by Bioz Stars, 2026-02
93/100 stars
  Buy from Supplier
pan caspase inhibitor z vad fmk  (TargetMol)
94
TargetMol pan caspase inhibitor z vad fmk
(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of <t>the</t> <t>pan-caspase</t> inhibitor <t>z-VAD-fmk.</t> (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
Pan Caspase Inhibitor Z Vad Fmk, supplied by TargetMol, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/pan caspase inhibitor z vad fmk/product/TargetMol
Average 94 stars, based on 1 article reviews
pan caspase inhibitor z vad fmk - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier

Image Search Results


(A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of the pan-caspase inhibitor z-VAD-fmk. (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Journal: bioRxiv

Article Title: tRF-3021a, a tRNA-Ala-TGC derived 3’ fragment, promotes glioblastoma cell invasion, suppresses apoptosis, and is required for normal levels of protein synthesis

doi: 10.64898/2026.01.26.701835

Figure Lengend Snippet: (A) Time course quantification of apoptotic (Annexin V–positive) U251 cells after transfection with negative control (NC) LNA or tRF-3021a LNA at the indicated time points. (B) Immunoblot time course of cleaved PARP in U251 cells following tRF-3021a knockdown (KD) versus NC LNA; GAPDH serves as a loading control. (C) Puromycin -labeling time course in U251 cells following tRF-3021a KD versus NC LNA. Cells were incubated with puromycin, and lysates were immunoblotted with anti-puromycin to assess global protein synthesis; GAPDH serves as a loading control. (D) Time course immunoblot analysis (2–12 h) of translation-regulatory signaling following tRF-3021a KD versus NC LNA, including total and phospho-eIF2α, total and phospho-p70S6 kinase (Thr389), and phospho-4E-BP1 (Thr37/46); GAPDH serves as a loading control. (E) Quantification of apoptotic (Annexin V–positive) cells after tRF-3021a KD in the presence or absence of the pan-caspase inhibitor z-VAD-fmk. (F) Puromycin-labeling assay at 48 h in U251 cells transfected with NC LNA, tRF-3021a LNA, tRF-3021a LNA + z-VAD-fmk or treated with z-VAD-fmk alone. Statistics: multiple unpaired two-tailed t tests comparing KD to NC at each time point with Benjamini–Krieger–Yekutieli false-discovery-rate correction (Q = 1%); p = 0.007751 (12 h), p = 0.000205 (24 h), p < 0.000001 (48 h). (E) one-way ANOVA with Tukey’s multiple-comparisons test; p = 0.0316 for KD versus KD + z-VAD. Significance: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.

Article Snippet: For chemical treatment, cells were treated with the pan-caspase inhibitor z-VAD-fmk (InvivoGen, tlrl-vad) at a final concentration of 20 μM for 48 h. To maintain inhibition, fresh z-VAD-fmk was added again at 24 h.

Techniques: Transfection, Negative Control, Western Blot, Knockdown, Control, Labeling, Incubation, Two Tailed Test